Get started
Author

Amy G. Edgecomb

Observed names: A Edgecomb, A. Edgecomb, AMY EDGECOMB, Amy Edgecomb, Amy G Edgecomb
Observed institution: GlaxoSmithKline (United States)
OpenAlex ID: A5093862012
Definitions and rates of treatment failure in females with uncomplicated urinary tract infection: a systematic literature review
2026 · Meghan E Luck, Amber Martin, et al. · Journal of Antimicrobial Chemotherapy · 3
Burden of hypereosinophilic syndromes in the United States: Patients’ perspective
2025 · Jared Silver, Anna Kovalszki, et al. · Journal of Allergy and Clinical Immunology Global · 3
Corticosteroid-sparing/end-organ Manifestation Benefits Observed in Real-world Patients With Hypereosinophilic Syndrome/eosinophilic Granulomatosis With Polyangiitis Receiving Mepolizumab
2024 · A. Kovalszki, M. Wechsler, et al. · Annals of Allergy Asthma & Immunology · 2
PDF
Pulmonary Function and Asthma Control in Patients With Eosinophilic Granulomatosis With Polyangiitis or Hypereosinophilic Syndrome and Comorbid Asthma Treated With Mepolizumab
2024 · MICHAEL E WECHSLER, ANNA KOVALSZKI, et al. · CHEST Journal · 2
Real-world Mepolizumab Use in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Demonstrates Improvement in End-organ Manifestations and Long-term Corticosteroid Benefit: An Analysis of Allergy Practices in the United States
2024 · M.E. Wechsler, J. Silver, et al. · 2
A Real-World Study of Mepolizumab in Patients with EGPA and HES: Insights in Rare Eosinophilic Disease
2024 · Thanai Pongdee, Jared Silver, et al. · Journal of Allergy and Clinical Immunology · 2
Disease Severity and Healthcare Costs Associated With Chronic Kidney Disease in Patients With Systemic Lupus Erythematosus
2026 · Amy G. Edgecomb, Shirley P. Huang, et al. · Clinical Therapeutics · 1
PDF
Mepolizumab Improves Patient-Reported Outcomes and Reduces Treatment Burden in Patients With Chronic Rhinosinusitis With Nasal Polyps: A Real-World Chart Review Study
2025 · Amy Edgecomb, Jared Silver, et al. · Journal of Allergy and Clinical Immunology · 1
Mepolizumab Reduces Systemic Corticosteroid (SCS)-Related Toxicities Compared to Chronic SCS Use in Patients with EGPA
2025 · Thanai Pongdee, Arijita Deb, et al. · Journal of Allergy and Clinical Immunology · 1
PDF
When Empiric Therapy Fails: Clinical and Economic Consequences in uUTIs Among US Women
2026 · Debra L. Fromer, Jeffrey J. Ellis, et al. · Microorganisms
Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study
2026 · Thanai Pongdee, Jared Silver, et al. · Frontiers in Allergy
PDF
Additional file 1 of Mepolizumab reduces healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps: a linked EMR and claims-based pre-post study
2026 · Anna Swenson, Waseem Ahmed, et al. · Figshare
Mepolizumab reduces healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps: a linked EMR and claims-based pre-post study
2026 · Anna Swenson, Waseem Ahmed, et al. · Allergy Asthma and Clinical Immunology
Ee440 Post-discharge Treatment Pathways After Iv Therapy for Complicated Uti Including Acute Pyelonephritis: Implications for Length of Stay, Costs, and Treatment Failure
2026 · Amy G. Edgecomb, thomas lodise, et al. · Value in Health
Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES
2026 · Michael E. Wechsler, Anna Kovalszki, et al. · Journal of Allergy and Clinical Immunology Global
P-786. Comparison of Length of Stay and Hospitalization Costs Among Patients with Complicated Urinary Tract Infection including Acute Pyelonephritis by Antibiotic Hospital Discharge Treatment Strategy
2026 · Thomas Lodise, Amy G Edgecomb, et al. · Open Forum Infectious Diseases
PDF
S162 Emerging biologic use may reduce the need for corticosteroid treatment and surgery for chronic rhinosinusitis with nasal polyps (CRSwNP) in France, Germany, Italy, Spain and the UK
2025 · W Ahmed, J Hwee, et al.
Impact of empirical treatment failure on health care resource utilization and costs among female patients with uncomplicated urinary tract infections in a US-based Integrated Health Delivery Network
2025 · Jeffrey J. Ellis, Anushree Iyengar, et al. · Journal of Managed Care & Specialty Pharmacy
Mepolizumab for the management of chronic rhinosinusitis with nasal polyps across the United States: A retrospective study
2025 · Juan Carlos Cardet, Jared Silver, et al. · Journal of Allergy and Clinical Immunology Global
A Novel Approach of Identifying Real-World Patients with Chronic Rhinosinusitis With Nasal Polyps in the USA Using an Electronic Health Records-Based Algorithm
2025 · Anju Peters, Rebecca Fee, et al. · Journal of Allergy and Clinical Immunology
Development of an Algorithm to Identify Patients With Hypereosinophilic Syndrome (HES) in Claims Data and Electronic Health Records
2025 · Thanai Pongdee, Valery Walker, et al. · Journal of Allergy and Clinical Immunology
Real-world Mepolizumab Use for Chronic Rhinosinusitis With Nasal Polyps and Severe Asthma Improves Clinical/economic Outcomes
2024 · J. Cardet, M. Maldonado-Puebla, et al. · Annals of Allergy Asthma & Immunology
PDF
Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: A Pre/Post Assessment of Oral Corticosteroid Use and Sinus Surgery in the US
2024 · Martin Maldonado-Puebla, Juan Carlos Cardet, et al. · Journal of Allergy and Clinical Immunology
Works count: 23
Citation count: 17
H-index: 2
I10-index:
Year
Topic
Type